JACC Heart Fail:西格列汀或增心衰住院风险

2014-07-10 高晓方 译 医学论坛网

加拿大一项研究表明,在初始伴有心衰的糖尿病患者中,DPP-4抑制剂西格列汀可升高心衰住院风险。 此项研究共纳入7620例接受二甲双胍或磺酰脲治疗且伴有心衰的糖尿病患者,其中887例在诊断心衰后启用西格列汀。主要终点为全因住院或死亡,次要终点为心衰住院、全因死亡或全因住院。中位随访时间为1.4年。 结果显示,在未校正分析中西格列汀应用和未应用者的主要终点和次要终点均无显著差异

加拿大一项研究表明,在初始伴有心衰的糖尿病患者中,DPP-4抑制剂西格列汀可升高心衰住院风险。

此项研究共纳入7620例接受二甲双胍或磺酰脲治疗且伴有心衰的糖尿病患者,其中887例在诊断心衰后启用西格列汀。主要终点为全因住院或死亡,次要终点为心衰住院、全因死亡或全因住院。中位随访时间为1.4年。




结果显示,在未校正分析中西格列汀应用和未应用者的主要终点和次要终点均无显著差异,但西格列汀应用者的心衰住院率显著升高(比值比[OR] 1.84;P=0.01)。西格列汀导致新发心衰住院风险升高84%,造成伤害所需治疗人数为29。此外,二甲双胍治疗与主要终点相对风险降低22%相关,磺脲类和胰岛素应用者的主要终点风险则分别升高10%和16%。

研究者表示,西格列汀所致的心衰住院风险升高可能具有临床意义,并且对心衰患者选择附加糖尿病治疗药物可能具有指导价值。鉴于DPP-4抑制剂心衰风险临床研究结果并不一致,因此未来需进一步明确西格列汀的风险及获益特征。

原始出处:

Weir DL1, McAlister FA2, Senthilselvan A3, Minhas-Sandhu JK4, Eurich DT5.Sitagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study.JACC Heart Fail. 2014 Jun 25. pii: S2213-1779(14)00194-2. doi: 10.1016/j.jchf.2014.04.005. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853284, encodeId=bdf2185328435, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 16:50:00 CST 2015, time=2015-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055865, encodeId=2fee20558659d, content=<a href='/topic/show?id=074651931a0' target=_blank style='color:#2F92EE;'>#心衰住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51931, encryptionId=074651931a0, topicName=心衰住院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 15 15:50:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251703, encodeId=da701251e03e8, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324943, encodeId=f9a8132494368, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355885, encodeId=2e03135588539, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562249, encodeId=5fcd15622491b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
    2015-03-30 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853284, encodeId=bdf2185328435, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 16:50:00 CST 2015, time=2015-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055865, encodeId=2fee20558659d, content=<a href='/topic/show?id=074651931a0' target=_blank style='color:#2F92EE;'>#心衰住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51931, encryptionId=074651931a0, topicName=心衰住院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 15 15:50:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251703, encodeId=da701251e03e8, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324943, encodeId=f9a8132494368, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355885, encodeId=2e03135588539, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562249, encodeId=5fcd15622491b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853284, encodeId=bdf2185328435, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 16:50:00 CST 2015, time=2015-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055865, encodeId=2fee20558659d, content=<a href='/topic/show?id=074651931a0' target=_blank style='color:#2F92EE;'>#心衰住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51931, encryptionId=074651931a0, topicName=心衰住院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 15 15:50:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251703, encodeId=da701251e03e8, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324943, encodeId=f9a8132494368, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355885, encodeId=2e03135588539, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562249, encodeId=5fcd15622491b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853284, encodeId=bdf2185328435, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 16:50:00 CST 2015, time=2015-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055865, encodeId=2fee20558659d, content=<a href='/topic/show?id=074651931a0' target=_blank style='color:#2F92EE;'>#心衰住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51931, encryptionId=074651931a0, topicName=心衰住院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 15 15:50:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251703, encodeId=da701251e03e8, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324943, encodeId=f9a8132494368, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355885, encodeId=2e03135588539, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562249, encodeId=5fcd15622491b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853284, encodeId=bdf2185328435, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 16:50:00 CST 2015, time=2015-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055865, encodeId=2fee20558659d, content=<a href='/topic/show?id=074651931a0' target=_blank style='color:#2F92EE;'>#心衰住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51931, encryptionId=074651931a0, topicName=心衰住院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 15 15:50:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251703, encodeId=da701251e03e8, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324943, encodeId=f9a8132494368, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355885, encodeId=2e03135588539, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562249, encodeId=5fcd15622491b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
    2014-07-12 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853284, encodeId=bdf2185328435, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 16:50:00 CST 2015, time=2015-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055865, encodeId=2fee20558659d, content=<a href='/topic/show?id=074651931a0' target=_blank style='color:#2F92EE;'>#心衰住院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51931, encryptionId=074651931a0, topicName=心衰住院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sun Mar 15 15:50:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251703, encodeId=da701251e03e8, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324943, encodeId=f9a8132494368, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355885, encodeId=2e03135588539, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562249, encodeId=5fcd15622491b, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jul 12 00:50:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]

相关资讯

西格列汀和兰索拉唑组合有助于1型糖尿病患者

桑福德项目的研究者在临床试验中建立个一个里程碑,该项试验是验证两种药物的混合是否能有助于1型糖尿病人,在不使用或少使用胰岛素的情况下,使患者血糖水平保持在可控范围之内。在需要完成I期临床试验的全部患者中,都发生了被称之为“胰腺修复”的反应。在“胰腺修复”试验中,对两种FDA批准的药物——西格列汀和兰索拉唑潜在的临床效益进行了评估。试验需要54名参与者完成一项持续24个月的研究,其中有36名患者服用

专家共话西格列汀在心血管病防治中的作用

       二肽基肽酶4(DPP-4)抑制剂西格列汀等基于肠促胰素的治疗是近年来糖尿病研究领域的热点,2012年美国糖尿病学会(ADA)和欧洲糖尿病研究学会(EASD)更新的共识意见中已指出,基于肠促胰素的治疗进入了日常临床实践。随着这类药物临床应用经验的积累,人们对其临床应用特点的认识也更加深入。本届ADA年会中,丹麦迪肯(Carol

ADA 2013:礼来旗下长效糖尿病药物Dulaglutide后期临床试验表现突出

根据后期临床试验结果,礼来开发的一款一周注射一次的2型糖尿病药物Dulaglutide在控制血糖方面较其它3种被广泛应用的药物更加有效。在6月22日从芝加哥举行的美国糖尿病协会(ADA)年会上公布的研究数据也显示礼来的这款糖尿病药物有助于减轻患者的体重,其效果是默沙东西格列汀(年销售额达40亿美元)的两倍。 三项后期临床试验结果表明,这款名为Dulaglutide的治疗药物可能会是对抗2型糖尿病

EASD 2013:西格列汀可保护LADA患者β细胞功能

成人迟发型自身免疫性糖尿病(LADA)被认为是由慢性胰腺β细胞自身免疫损伤引起。LADA理想的治疗方案应以促进β细胞增殖和调节免疫系统为目的。体外实验中肠促胰岛素类药物二肽基肽酶-4(DPP-4)抑制剂可以刺激β细胞增殖,以及增加胰岛素含量,并且已被证明可以改善2型糖尿病患者β细胞功能。另外,DPP-4抑制剂同时在免疫调节中发挥重要作用,提别是T细胞活化。因此,假释LADA患者可以从DPP-4抑制

Diabetes Care:Canagliflozin降糖效果不劣于西格列汀

    对于二甲双胍联合磺脲类药物血糖控制不佳的2型糖尿病患者,canagliflozin [一种钠—葡萄糖协同转运子2(SGLT2)抑制剂] 或可成为糖尿病治疗的又一选择。在一项3期临床试验中canagliflozin显示出降糖与体重改善方面相对于西格列汀的优势,但研究同时指出服用canagliflozin的女性患者需注意生殖器真菌感染风险。该研究2013年4月5

Am J Kidney Dls:降糖药物或使肾病透析患者获益

  美国一项随机双盲试验显示,对于2型糖尿病和接受透析治疗的终末期肾脏病(ESRD)患者,使用西格列汀或格列吡嗪单药治疗54周以上有效且耐受性良好。   该研究纳入年龄为30岁及以上罹患2型糖尿病和接受透析治疗的ESRD 者129例,且糖化血红蛋白(HbAlc)为7%、9%,将其按1:1随机分为西格列汀组(n=64,25 tng/d,平均年龄为61岁,Hb/Uc为7.&nbs